{"id":"NCT00647400","sponsor":"Abbott","briefTitle":"Adalimumab in Adult Japanese Subjects With Psoriasis","officialTitle":"A Multicenter Open-Label Continuation Study of the Long-term Safety and Efficacy of Adalimumab (D2E7) in Japanese Subjects With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2006-04","primaryCompletion":"2007-09","completion":"2010-04","firstPosted":"2008-03-31","resultsPosted":"2010-01-11","lastUpdate":"2011-04-08"},"enrollment":147,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Psoriasis"],"interventions":[{"type":"BIOLOGICAL","name":"adalimumab","otherNames":["ABT-D2E7","Humira"]},{"type":"BIOLOGICAL","name":"adalimumab","otherNames":["ABT-D2E7","Humira"]}],"arms":[{"label":"Adalimumab 40 mg every other week","type":"EXPERIMENTAL"},{"label":"Adalimumab 80 mg every other week","type":"EXPERIMENTAL"}],"summary":"To evaluate efficacy, safety, and pharmacokinetics of adalimumab in Japanese participants with psoriasis","primaryOutcome":{"measure":"Number of Participants With a 50% Reduction in PASI (Psoriasis Area and Severity Index) Score Compared With Baseline PASI Score (PASI50 Response)","timeFrame":"Baseline and 12, 24, 36, 52, 76, 100, 160, and 208 weeks after the first dose of adalimumab","effectByArm":[{"arm":"Adalimumab 40 mg Every Other Week","deltaMin":78,"sd":null},{"arm":"Adalimumab 80 mg Every Other Week","deltaMin":54,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":64,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":19,"n":89},"commonTop":["Nasopharyngitis","Blood triglycerides increased","Blood creatine phosphokinase increased","Folliculitis","Diarrhoea"]}}